Seize the digital momentum

January 23, 2023

Investments in biopharmaceutical (biopharma) research and development (R&D) continue to fuel innovation and shape the future of health. However, this year’s analysis demonstrates that despite impressive examples of innovative products the step-change in improved productivity seen in 2021 has not continued.

Spotlight

Sutherland Healthcare Solutions

Analytics-driven business process and technology solutions to optimize healthcare’s financial and clinical performance. We are a leading provider of consulting, process transformation services, information technology (IT) optimization, analytics, and design thinking solutions to the entire healthcare ecosystem. We have 5,000 dedicated employees in 15+ global sites delivering customized and scalable solutions, including: contact center, coding, revenue cycle management, healthcare IT, provider data management, experience consulting, and population and payment solutions.

OTHER WHITEPAPERS

Pharma R And D Review

whitePaper | February 11, 2021

Welcome to Pharmaprojects’ 2021 review of trends in pharmaceutical R&D. For almost 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article I’ll examine the state of play at the start of 2021.

Four best practices for single-use supply chain success

whitePaper | February 16, 2023

Flexible and cost-effective, single-use technologies offer biopharmaceutical companies a way to transform their biologics production and meet the growing demand for these life-changing therapies.

The Key to Commercializing Revolutionary Gene Therapiesand Other Orphan Drugs

whitePaper | October 27, 2022

In today’s evolving, value-based environment for specialty drugs, hightouch services that enhance patient outcomes are playing an increasingly important role in market access and patient care delivery

Multi-channel clinical trial recruitment technology checklist

whitePaper | August 8, 2022

Biopharma R&D professionals generally admit that the current "high-cost, high-risk" development model is unsustainable. Despite technological.

Pharma R&D Annual Review

whitePaper | March 15, 2022

Successes in 2021 – New active substance drug launches

Simcyp™ PBPK for Drug-Drug Interactions (DDI)

whitePaper | July 4, 2023

The past two decades have witnessed transformative changes in our approach to using modeling & simulation to assess and manage DDIs. Multidisciplinary innovations in mechanistic assessment of absorption, distribution, metabolism, and excretion (ADME), population pharmacology and pharmacogenetics.

Pharmacy Market

Seize the digital momentum